Endoscopic correction of vesicoureteral reflux after chemodenervation of the detrusor with botulinum toxin in a child with a neurogenic bladder and myelodysplasia. Case report

封面

如何引用文章

全文:

详细

Correction of vesicoureteral reflux in children with neurogenic bladder (NB) and myelodysplasia is rather challenging due to the presence of two aggravating factors. The first is the trabecularity of the bladder due to chronic ischemia and dysfunction of the closing contraction of the ureteral orifice up to complete deconfiguration of the ureterovesical junction, and the second is the neurogenic hyperactivity of the detrusor with hypertonicity, intravesical hypertension, and a significant decrease in the effective volume of the bladder. These pathophysiological mechanisms reduce to zero the effectiveness of open reimplantation of the ureter to create an anti-reflux mechanism, becoming, on the contrary, the cause of reflux aggravation and the development of ureterohydronephrosis. As a result, the correction of reflux in NB becomes impossible without stabilization of detrusor contractility, elimination of intravesical hypertension, and correction of spastic changes in the bladder. Clinical follow-up of a patient with this disorder for 10 years convincingly proves the effectiveness of step-by-step correction of NB and vesicoureteral reflux while adhering to the order of treatment methods.

全文:

受限制的访问

作者简介

Maksim Romashin

Pirogov Russian National Research Medical University; Speransky City Clinical Children’s Hospital №9

编辑信件的主要联系方式.
Email: romashinmaxim17@yandex.ru
ORCID iD: 0000-0003-3480-9812

Res. Assist.

俄罗斯联邦, Moscow; Moscow

Natalia Guseva

Pirogov Russian National Research Medical University; Speransky City Clinical Children’s Hospital №9; Russian Medical Academy of Continuous Professional Education

Email: guseva-n-b@yandex.ru
ORCID iD: 0000-0002-1583-1769

D. Sci. (Med.)

俄罗斯联邦, Moscow; Moscow; Moscow

Elena Mlynchik

Speransky City Clinical Children’s Hospital №9

Email: mlynchik@yandex.ru
ORCID iD: 0000-0003-2606-1218

Сand. Sci. (Med.)

俄罗斯联邦, Moscow

参考

  1. Edwards A, Peters CA. Managing vesicoureteral reflux in children: making sense of all the data. F1000Res. 2019;8. doi: 10.12688/f1000research.16534.1
  2. Sager C, Barroso U Jr, Bastos JM Netto, et al. Management of neurogenic bladder dysfunction in children update and recommendations on medical treatment. Int Braz J Urol. 2022;48(1):31-51. doi: 10.1590/S1677-5538.IBJU.2020.0989
  3. Гусева Н.Б., Игнатьев Р.О., Заботина Э.К., Пономарева Т.Н. Клинические особенности нейрогенного мочевого пузыря, осложненного пузырно-мочеточниковым рефлюксом, у детей с миелодисплазией. Российский вестник детской хирургии, анестезиологии и реаниматологии. 2012;2(2):38-45 [Guseva NB, Ignatiev RO, Zabotina EK, Ponomareva TN. Clinical features of neurogenic bladder, complicated vesicoureteral reflux, in children with myelodysplasia. Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care. 2012;2(2):38-45 (in Russian)].
  4. Miyakita H, Hayashi Y, Mitsui T, et al. Guidelines for the medical management of pediatric vesicoureteral reflux. Int J Urol. 2020;27(6):480-90. doi: 10.1111/iju.14223
  5. Naseri M, Tafazoli N, Tafazoli N. Prevalence of Vesicoureteral Reflux in Children with Urinary Tract Infection. Saudi J Kidney Dis Transpl. 2022;33(Suppl.):S111-20. doi: 10.4103/1319-2442.384183
  6. Shen M, Pan XY, Zhuang JQ, et al. Clinical features of neurogenic bladder with vesicoureteral reflux in children. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(3):279-82. doi: 10.7499/j.issn.1008-8830.2011131
  7. Andrioli V, Regacini R, Aguiar W. Primary Vesicoureteral reflux and chronic kidney disease in pediatric population. What we have learnt? Int Braz J Urol. 2020;46(2):262-8. doi: 10.1590/S1677-5538.IBJU.2020.02.02
  8. Kurt-Sukur ED, Özçakar ZB, Haznedar-Karakaya P, et al. Clinical characteristics and outcome of childhood vesicoureteral reflux. Arch Argent Pediatr. 2020;118(1):e16-21. doi: 10.5546/aap.2020.eng.e16
  9. Wu CQ, Franco I. Management of vesicoureteral reflux in neurogenic bladder. Investig Clin Urol. 2017;58(Suppl. 1):S54-8. doi: 10.4111/icu.2017.58.S1.S54
  10. Roupakias S, Sinopidis X, Spyridakis I, et al. Endoscopic Injection Treatment of Vesicoureteral Reflux in Children: Meeting with the Factors Involved in the Success Rate. Acta Medica (Hradec Kralove). 2021;64(4):193-9. doi: 10.14712/18059694.2022.1
  11. Escolino M, Kalfa N, Castagnetti M, et al. Endoscopic injection of bulking agents in pediatric vesicoureteral reflux: a narrative review of the literature. Pediatr Surg Int. 2023;39(1):133. doi: 10.1007/s00383-023-05426-w
  12. Wu SY, Chang SJ, Yang SS, Hsu CK. Botulinum Toxin Injection for Medically Refractory Neurogenic Bladder in Children: A Systematic Review. Toxins (Basel). 2021;13(7). doi: 10.3390/toxins13070447

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Baseline cystoureterography.

下载 (160KB)
3. Fig. 2. Cystoureterography after detrusor chemodenervation with type A botulinum toxin and endoscopic reflux correction.

下载 (174KB)

版权所有 © Consilium Medicum, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.